The company was founded as a strategic partnership with the world's leading biopharmaceutical company to deliver innovative drugs to patients in Asia and around the world Press release.

Overland Pharmaceuticals, backed by global investment agency Technology, officially launched on December 9th.
aims to build biopharmaceutical companies with a full range of research and development capabilities through strategic cooperation in specific disease areas, providing innovative drugs to address the unseeded clinical needs of patients in Asia and around the world.
Pharmaceuticals will use a team with international and local research and development experience and excellent performance to work effectively with partners.
is founded by MD PhD, in chief executive officer and chief medical officer, and Zhang Xiaolei (MBA), chief operating officer and chief commercial officer, both experienced life sciences veterans with outstanding leadership in international cooperation in biopharmaceuticals.
will operate in Shanghai, China, Beijing and Boston, Massachusetts.
With its global network in biomedicine and the active biopharmaceutical ecosystem in Asia,
is committed to building multi-faceted partnerships with biopharmaceutical companies with cutting-edge technology platforms to accelerate the development and commercialization of these cutting-edge technologies and innovative therapies.
partnered with ADC Therapeutics to develop and commercialize Lonca and other antibody-coupled drugs ADC Therapeutics SA (NYSE code-named ADCT) and Tolu Pharmaceuticals on December 14, 2020 to formally announce the establishment of a joint venture (Overland ADCT BioPharma) to develop and commercialize four antibody-coupled drugs for the treatment of resusable blood tumors and solid tumors in Greater China and Singapore.
based on the partnership agreement, Lulu Pharmaceuticals will invest $50 million in a joint venture with a 51% stake and ADC Therapeutics with a 49% stake.
ADC Therapeutics also receives milestone payments and sales credits from licensing agreements with Overland ADCT BioPharma.
most important product in Overland ADCT BioPharma's product pipeline is Lonca.
The product is an antibody-coupled drug that contains humanized monoclonal antibodies directly acting on CD19 targets, and its new drug listing application (BLA) was recently formally accepted by the U.S. Drug Administration (FDA) and granted priority review eligibility.
Lonca's clinical efficacy has been evaluated in a critical Phase II clinical trial in patients with recurring diffetic large B-cell lymphoma (DLBCL), and two clinical trials are currently under way, one in recurring recurring resuscable DLBCL Phase I./II. clinical trials conducted in patients with lymphoma (MCL) in patients with Lonca and Ibdinib, and another phase III. confirmed clinical trial conducted in patients with recurring recurring incurable DLBCL.
Overland ADCT BioPharma's product pipeline also includes ADCT-602 for CD22 targets and ADCT-601 for AXL targets, as well as ADCT-901 for KAAG1 targets.
ADCT-901 is currently used in preclinical research and development for the treatment of advanced solid tumors with highly unsystressed clinical needs.
developed and commercialized Allogene Therapeutics, Inc. in partnership with Allogene Therapeutics, Inc., a leading global company in the development of alloCAR T™ for cancer treatment, and is currently in clinical development™.
announced a joint venture with Allogene Overland Biopharm on December 15, 2020, focusing on the development, production and commercialization of AlloCAR T therapies for patients in Greater China, Korea and Singapore.
the joint venture will also advance the global development of AlloCAR T Therapy.
terms of the agreement, the joint venture will obtain exclusive license for AlloCAR T candidates targeting BCMA, CD70, FLT3 and DLL3 in these regions.
will invest $117 million, including a $40 million down payment to Allogene and $77 million to support the joint venture's operations.
and Allergogene are the sole shareholders in the joint venture Allogene Overland Biopharm.
the first time each product is licensed in China, Allogene will be eligible for milestone payments for that product, as well as a tiered sales share of net sales.
will provide development and operational support, while Allergogene will provide technical and production guidance.
。